AstraZeneca: Imfinzi Granted Priority Review in the US for Patients With Muscle-Invasive Bladder Cancer
December 07, 2024
December 07, 2024
WILMINGTON, Delaware, Dec. 7 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Decision based on NIAGARA Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free and overall survival benefit
If approved, this will be the first and only perioperative immunotherapy regimen in this curative-intent setting
* * *
AstraZeneca's supplement . . .
* * *
Decision based on NIAGARA Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free and overall survival benefit
If approved, this will be the first and only perioperative immunotherapy regimen in this curative-intent setting
* * *
AstraZeneca's supplement . . .